Complete financial analysis of Panbela Therapeutics, Inc. (PBLA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Panbela Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Angold Resources Ltd. (AAUGF) Income Statement Analysis – Financial Results
- AsiaFIN Holdings Corp. (ASFH) Income Statement Analysis – Financial Results
- Yeong Hwa Metal Co., Ltd. (012280.KS) Income Statement Analysis – Financial Results
- Dynamics Special Purpose Corp. (DYNS) Income Statement Analysis – Financial Results
- ACTIA Group S.A. (ALATI.PA) Income Statement Analysis – Financial Results
Panbela Therapeutics, Inc. (PBLA)
About Panbela Therapeutics, Inc.
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.36M | 973.81K | 1.23M | 699.76K |
| Cost of Revenue | 25.65M | 35.73M | 10.01M | 5.75M | 4.32M | 3.89M | 6.02M | 5.17M | 5.44M | 595.15K | 558.47K | 691.80K | 550.54K |
| Gross Profit | -25.65M | -35.73M | -10.01M | -5.75M | -4.32M | -3.89M | -6.02M | -5.17M | -5.44M | 761.84K | 415.35K | 540.90K | 149.21K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 56.14% | 42.65% | 43.88% | 21.32% |
| Research & Development | 20.61M | 28.05M | 5.42M | 2.51M | 2.35M | 1.78M | 2.59M | 2.50M | 2.85M | 2.37K | 279.79K | 0.00 | 0.00 |
| General & Administrative | 5.03M | 6.04M | 4.59M | 3.25M | 1.97M | 2.11M | 3.42M | 2.66M | 2.81M | 837.24K | 329.88K | 258.10K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -217.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.03M | 6.04M | 4.59M | 3.25M | 1.97M | 2.11M | 3.42M | 2.66M | 2.59M | 837.24K | 329.88K | 258.10K | 253.72K |
| Other Expenses | 0.00 | -682.00K | -602.00K | 605.00K | -99.00K | -508.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 253.72K |
| Operating Expenses | 25.65M | 34.09M | 10.01M | 5.75M | 4.32M | 3.84M | 6.02M | 5.17M | 5.44M | 837.24K | 609.67K | 258.10K | 253.72K |
| Cost & Expenses | 51.29M | 34.09M | 10.01M | 5.75M | 4.32M | 3.84M | 6.02M | 5.17M | 5.44M | 1.43M | 1.17M | 949.90K | 804.26K |
| Interest Income | 123.00K | 14.00K | 1.00K | 17.00 | 2.19K | 0.00 | 1.00K | 2.00K | 8.00K | 4.00K | 18.41K | 0.00 | 0.00 |
| Interest Expense | -317.00K | 288.00K | 11.00K | 17.00K | 2.19M | 1.81M | 1.62M | 180.00K | 183.00K | 35.53K | 35.89K | 36.14K | 34.27K |
| Depreciation & Amortization | 0.00 | 16.36K | 10.01K | 5.75K | 4.32K | 3.89K | 6.02K | 5.17K | 8.00K | 9.58K | 8.79K | 5.64K | 3.10K |
| EBITDA | -51.29M | -34.76M | -10.61M | -5.15M | -4.42M | -1.76M | -6.02M | -5.17M | -5.12M | -75.40K | -194.32K | 289.44K | -101.40K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4.56% | -17.16% | 23.40% | -14.49% |
| Operating Income | -51.29M | -34.09M | -10.01M | -5.75M | -4.32M | -3.89M | -6.02M | -5.17M | -5.44M | -75.40K | -194.32K | 282.80K | -104.50K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5.56% | -19.95% | 22.94% | -14.93% |
| Total Other Income/Expenses | 25.85M | -956.00K | -613.00K | 691.00K | -2.29M | -2.27M | -4.89M | -285.00K | -564.00K | -31.53K | -17.48K | -35.14K | -33.69K |
| Income Before Tax | -25.45M | -35.05M | -10.62M | -5.06M | -6.62M | -6.16M | -10.91M | -5.45M | -5.68M | -106.92K | -211.80K | 247.66K | -138.20K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7.88% | -21.75% | 20.09% | -19.75% |
| Income Tax Expense | -186.00K | -116.00K | -488.00K | -295.00K | -415.00K | -254.00K | -536.00K | -341.00K | -756.00K | 121.00 | 220.00 | 284.00 | 115.00 |
| Net Income | -25.26M | -34.93M | -10.14M | -4.77M | -6.20M | -5.91M | -10.37M | -5.11M | -4.93M | -107.04K | -212.02K | 247.38K | -138.31K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7.89% | -21.77% | 20.07% | -19.77% |
| EPS | -232.43K | -40.75K | -20.77K | -14.80K | -26.10K | -1.52K | -3.49K | -1.97K | -4.20K | -892.03 | -1.77K | 2.06K | -1.15K |
| EPS Diluted | -232.43K | -40.75K | -20.77K | -14.80K | -26.10K | -1.52K | -3.49K | -1.97K | -4.20K | -892.03 | -1.77K | 2.06K | -1.15K |
| Weighted Avg Shares Out | 108.69 | 857.28 | 487.88 | 322.20 | 237.51 | 3.89K | 2.97K | 2.59K | 1.17K | 120.00 | 120.00 | 120.00 | 120.00 |
| Weighted Avg Shares Out (Dil) | 108.69 | 857.28 | 487.88 | 322.20 | 237.51 | 3.89K | 2.97K | 2.59K | 1.17K | 120.00 | 120.00 | 120.00 | 120.00 |
Panbela Therapeutics, Inc. (PBLA) Q3 2024 Earnings Call Transcript
Panbela Therapeutics, Inc. (OTCQB:PBLA) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Jennifer Simpson - CEO Sue Horvath - CFO Conference Call Participants Jonathan Aschoff - ROTH Capital Operator Greetings, and welcome to the Panbela...
Panbela Provides Business Update and Reports Q3 2024 Financial Results
MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended September...
Panbela Therapeutics, Inc. (PBLA) Q2 2024 Earnings Call Transcript
Panbela Therapeutics, Inc. (OTCQB:PBLA) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants James Carbonara - Hayden, IR Jennifer Simpson - President and Chief Executive Officer Susan Horvath - Vice President and Chief Financial Officer Conference...
Panbela Provides Business Update and Reports Q2 2024 Financial Results
MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June...
Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
MINNEAPOLIS, July 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on Aug...
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
MINNEAPOLIS, June 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the independent Data Safety Monitoring Board (DSMB) has...
Panbela Therapeutics, Inc. (NASDAQ:PBLA) to Post Q2 2024 Earnings of ($2.07) Per Share, HC Wainwright Forecasts
Panbela Therapeutics, Inc. (NASDAQ:PBLA – Free Report) – Analysts at HC Wainwright dropped their Q2 2024 earnings per share estimates for Panbela Therapeutics in a research note issued to investors on Thursday, May 16th. HC Wainwright analyst J. Pantginis now...
Panbela Therapeutics, Inc. (PBLA) Q1 2024 Earnings Call Transcript
Panbela Therapeutics, Inc. (OTC:PBLA) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants James Carbonara - IR, HaydenIR Jennifer Simpson - President & CEO Susan Horvath - CFO Conference Call Participants Jonathan Aschoff - Roth Capital...
Panbela Provides Business Update and Reports Q1 2024 Financial Results
MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended March...
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced an Issue Notification for the US continuation patent US 11,925,613 B2 and...
Source: https://incomestatements.info
Category: Stock Reports